Business Description
ME Therapeutics Holding Inc
NAICS : 541714
SIC : 3741
ISIN : CA5527671054
Description
ME Therapeutics Holding Inc operates its business through ME Therapeutics. It is a preclinical-stage biotechnology company working on novel cancer-fighting drugs in the field of Immuno-Oncology (IO). It is developing preclinical data for its myeloid-targeted candidate assets using validated cancer models.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 37.43 | |||||
| Equity-to-Asset | 0.96 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.03 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | N/A/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 27.2 | |||||
| 9-Day RSI | 33.24 | |||||
| 14-Day RSI | 37.04 | |||||
| 6-1 Month Momentum % | -12.5 | |||||
| 12-1 Month Momentum % | 250 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 24.41 | |||||
| Quick Ratio | 24.41 | |||||
| Cash Ratio | 23.76 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | 0.01 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -120.28 | |||||
| ROA % | -113.17 | |||||
| ROIC % | -4914.81 | |||||
| ROC (Joel Greenblatt) % | -9585.19 | |||||
| ROCE % | -120.26 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 50.85 | |||||
| Price-to-Tangible-Book | 50 | |||||
| EV-to-EBIT | -58.14 | |||||
| EV-to-EBITDA | -58.14 | |||||
| EV-to-FCF | -114.5 | |||||
| Price-to-Net-Current-Asset-Value | 50 | |||||
| Price-to-Net-Cash | 50 | |||||
| Earnings Yield (Greenblatt) % | -1.72 | |||||
| FCF Yield % | -0.87 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ME Therapeutics Holding Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil C$) | |||
| EPS (TTM) (C$) | -0.05 | ||
| Beta | 0 | ||
| Volatility % | 320.74 | ||
| 14-Day RSI | 37.04 | ||
| 14-Day ATR (C$) | 0.371383 | ||
| 20-Day SMA (C$) | 3.824 | ||
| 12-1 Month Momentum % | 250 | ||
| 52-Week Range (C$) | 0.75 - 7.5 | ||
| Shares Outstanding (Mil) | 25.19 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ME Therapeutics Holding Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ME Therapeutics Holding Inc Stock Events
| Event | Date | Price(C$) | ||
|---|---|---|---|---|
| No Event Data | ||||
ME Therapeutics Holding Inc Frequently Asked Questions
What is ME Therapeutics Holding Inc(XCNQ:METX)'s stock price today?
The current price of XCNQ:METX is C$3.00. The 52 week high of XCNQ:METX is C$7.50 and 52 week low is C$0.75.
When is next earnings date of ME Therapeutics Holding Inc(XCNQ:METX)?
The next earnings date of ME Therapeutics Holding Inc(XCNQ:METX) is .
Does ME Therapeutics Holding Inc(XCNQ:METX) pay dividends? If so, how much?
ME Therapeutics Holding Inc(XCNQ:METX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers